Dr Finn Holding

I have been using mass spectrometry (MS) in drug discovery for more than 20 years, firstly in the biotechnology sector before moving to the High Throughput Screening department at Astrazeneca. The capabilities of the various detection platforms of modern mass spectrometers coupled to the bolt on fluidic technologies applied to sample handing and manipulation make MS uniquely suitable for virtually all phases of the drug discovery (DD) process. My interest is in the development and application of additional MS methodologies to help drive the earlier stages of DD, and in particular for the identification of hit equity from screening of compound libraries.